Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future
Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...
Google DeepMind CEO says his passion for chess led to his career in AI
Demis Hassabis, a childhood chess prodigy, said his experience with the game afforded him his first brush with AI. He was ...
Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
University of Cambridge13d
Nobel laureate and Cambridge alumnus Sir Demis Hassabis heralds a new era of 'digital speed' drug discovery
Demis, who was last year jointly awarded the Nobel Prize in Chemistry with Google DeepMind colleague Dr John Jumper for their ...
Google replaces the leader of its consumer AI apps: report
Google reshuffles AI leadership with Sissie Hsiao stepping down and Josh Woodward stepping in to drive Gemini's evolution.
Alphabet spinout Isomorphic Labs raises $600M for its AI drug design engine
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Explore more
BioPharma Dive6d
Isomorphic raises $600M on big ambitions for AI drugmaking tech
The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...
GlobalData on MSN6d
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...